Clovertex Target of the Month (03/25): GSPT1

Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital role in protein synthesis and cell viability. As a substrate for targeted protein degradation, GSPT1 has attracted significant interest in the search for novel cancer therapies.

Monte Rosa Therapeutics recently presented early clinical data from its GSPT1 degrader program and announced a strategic narrowing of focus. The company is pausing work in most solid tumors - not due to lack of efficacy, but because of challenges in identifying the right biomarker-defined patient populations - while continuing clinical evaluation in prostate cancer. This comes amid a broader, mixed picture in the protein degradation space. Arvinas and Pfizer reported that their estrogen receptor degrader, vepdegestrant, met primary endpoints in a biomarker-selected subgroup, while missing the mark in the overall intent-to-treat population. Together, these developments highlight both the promise and complexity of degrader drugs, where clinical refinement - not retreat - is shaping the future of this modality.

The Protein Imager rendering displays the crystal structure of cereblon in complex with DDB1, CC-885, and GSPT1 (PDB entry 5HXB).  

About Clovertex

Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.

Useful links

1. New Clinical Results from MRT-6160 and MRT-2359 Programs

2. Clovertex website